US CRO Ockham Development group will start providing customers with data capture and analysis solutions developed by etrials under a new, five year licensing agreement.
Top 10 contract research organization (CRO) PharmaNet has gone into private hands following the conclusion of its acquisition by private equity firm JLL Partners.
Contract research firm Icon Clinical saw its revenues advance by nearly 22 per cent in the last quarter of 2008, but still saw its share price slide as investors got the jitters over the firm’s cautious predictions for 2009.
Patheon says the $183m (€142m) buy-out proposal by private equity group JLL Patheon Holdings is “opportunistic” and designed to take advantage of the recent stock-market related fluctuation in its valuation.
MDS has formed a special committee to improve shareholder value following poor results and pressure from investors to sell some of its business units, which include a CRO division.
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
Contract research organisation PharmaNet Development Group is considering a sale of the business as it tries to recover from a difficult year marked by shrinking revenues and cancelled contracts.
KV Pharmaceuticals’ long-serving CEO Marc Hermelin has either been sacked or has retired, depending on which party’s version of events one believes, and is being replaced by David Vliet CEO of the company’s Ethex division on an interim basis.
Packaging firm Chesapeake has become a visible casualty of the current economic climate, with the New York Stock Exchange (NYSE) suspending trading of its shares.
Roche offered this morning to take complete control of US biotechnology giant Genentech for the princely sum of $43.7bn in a move that it says would “enhance innovation” and cut costs for both companies.
Ranbaxy has claimed that a pharmaceutical company is making a
concerted effort to depress the company's share price by initiating
the accusations that the generics manufacturer falsified data to
achieve compliance.
Harvard Bioscience has rejected an unsolicited acquisition offer
from Skystone Advisors to acquire all outstanding shares of common
stock in the life science tools and instrument manufacturer.
Management of publicly-traded Synexus have agreed to the £18.1m
(€25.7m) sale of the company to a private equity firm that has
promised to fund its global expansion ventures.
Investors in Bristol-Myers Squibb were in a frisson of excitement
earlier this week as speculation mounted - not for the first time -
that the firm could soon become the target of a major
pharmaceutical acquisition.
A major shareholder in Bioenvision could seriously compromise the
biotech company's proposed $345m (€242m) takeover by Genzyme as it
is preparing to vote against the merger arguing the offer is too
low.
PRA said it signed an agreement with equity firm Genstar Capital to
be bought back by the firm for around $790m (€580m) while the CRO
posted a 90 per cent tumble in profit in Q2 due to heavy
restructuring charges.
The hook-up between German and French firms Sartorius and Stedim to
create a combined biotech business is now complete, with the deal
finalised and the new company ready to roll.
Canadian contract manufacturer Patheon has announced a $150m
(€114m) investment by a private equity firm - a move the company
sees as the best viable option to end its financial misery.
The High Court in the UK has granted an injunction to protect
GlaxoSmithKline (GSK) shareholders against the recent threat posed
by animal extremists, who contacted investors by mail warning them
to sell their shares in the company.
CFC International is to be acquired by Quad-C Management in a move
that aims to capitalise on the worldwide demand for CFC
International products that include hot stamp foils and heat
transferable labels for intravenous solution bags,...
Bayer stockholders have cleared the way for the spin-off of
chemical unit Lanxess, with voters holding 99.66 per cent of the
company's capital stock supporting the split.
Chemicals group Lanxess - to be spun out of Germany's Bayer next
year - plans to relocate a plant in Texas to China in order to tap
into the strong growth in the market for chemicals there.
Australian drug delivery company Acrux is hoping to raise A$30
million (€18m) in a float on the Australian Stock Exchange to
support the development of its novel transdermal technology that
does not require the use of adhesive patches...
Lanxess, the new company in which Germany's Bayer will combine
almost all areas of its chemicals business and parts of its
polymers activities, begins operating as an independent unit today.
October has seen a rush by US biotechnology companies to list on
the stock markets, bringing to an end an Initial Public Offering
(IPO) drought lasting more than 18 months. Is Europe destined to
follow?
Strasbourg, France-based Aventis has announced its intention to
sell off part of its remaining stake in Rhodia, its loss-making
former specialty chemicals subsidiary. The move reduces its stake
in Rhodia to 15.3 per cent from 25.2...
UK biotechnology bellwether Celltech has emerged victorious in the
bidding battle for Oxford GlycoSciences. OGS reluctantly gave in to
Celltech's pressure on 11 April, after the latter firm bought
additional holdings which brought...
